Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.72 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4258027 | 0.92 | MAOB (0.62) | MAOBAKR1B1EGFRSRCKMT2A | |
| SCHEMBL4254462 | 0.91 | MAOB (0.60) | MAOBAKR1B1EGFRSRCKMT2A | |
| SCHEMBL4247258 | 0.90 | MAOB (0.59) | MAOBAKR1B1EGFRSRCKMT2A | |
| SCHEMBL4249673 | 0.90 | MAOB (0.72) | MAOBAKR1B1SRCKMT2AL3MBTL1 | |
| SCHEMBL4253616 | 0.89 | MAOB (0.74) | MAOBAKR1B1EGFRSRCKMT2A | |
| SCHEMBL9635535 | 0.87 | MAOB (0.72) | MAOBAKR1B1KMT2AMEN1ATM | |
| SCHEMBL4253738 | 0.84 | MAOB (0.56) | MAOBAKR1B1EGFRSRCKMT2A | |
| SCHEMBL4250017 | 0.82 | MAOB (0.62) | MAOBAKR1B1SRCKMT2AL3MBTL1 | |
| SCHEMBL4246461 | 0.82 | KDM4E (0.59) | MAOBAKR1B1EGFRSRCMAPT | |
| SCHEMBL4251638 | 0.82 | MAOB (0.65) | MAOBAKR1B1KMT2AL3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2105431-A1 | Process for Producing Chromone Compound | Sumitomo Chemical Company, Limited (JP) | 2009-09-30 | — | — | EP | disclosed |
| EP-2105432-A1 | Process for Producing Chromone Compound | Sumitomo Chemical Company, Limited (JP) | 2009-09-30 | — | — | EP | disclosed |
| EP-1867626-A2 | Process for producing chromone compound | Sumitomo Chemical Company, Limited (JP) | 2007-12-19 | — | — | EP | disclosed |
| US-20060217565-A1 | Process for producing chromone compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-09-28 | — | — | US | disclosed |
| US-7094914-B2 | Process for producing chromone compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-08-22 | — | — | US | disclosed |
| US-20050085664-A1 | Process for producing chromone compound | SUMITOMO CHEMICAL COMPANY, LMITED (JP) | 2005-04-21 | — | — | US | disclosed |
| EP-1479667-A1 | PROCESS FOR PRODUCING CHROMONE COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2004-11-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085664-A1 | Process for producing chromone compound | ENY2, CDY1; CDY1B, CDYL | MAOB 476/4885AKR1B1 237/4885EGFR 3027/4885 |
| US-20060217565-A1 | Process for producing chromone compound | ENY2, CDY1; CDY1B, CDYL | MAOB 476/4885AKR1B1 237/4885EGFR 3027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.